메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

MALAYSIA HEALTHCARE TRAVEL COUNCIL LAUNCHES MYMT 2026, MALAYSIA'S FIRST MEDICAL TOURISM YEAR

KUALA LUMPUR, Malaysia, July 28, 2025 -- The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk Seri Dr. Dzulkefly Ahmad, Minister of Health Malaysia, officiated the event, unveiling the campaign's logo and tagline, "Healing Meets Hospitality." MYMT 2026 aims to position Malaysia as a premier medical tourism destination by showcasing its advanced healthcare services and hospitality. The campaign also seeks to attract international heal
- 김갑성 기자
- 2025-07-28 12:17
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

HONG KONG, July 28, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metasta
- 김갑성 기자
- 2025-07-28 12:14
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

SHANGHAI and HONG KONG, July 28, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17t
- 김갑성 기자
- 2025-07-28 10:40
Antengene Announces XPOVIO® Approved in China for the Second-Line Treatment of Multiple Myeloma, Marking the Third Approved Indication of the Drug

This approval for XPOVIO® in combination with bortezomib and dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy marks the third approved indication of the drug in China. XPOVIO® as a monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and in combination with dexamethasone in patients with R/R MM, two of the three approved indications of XPOVIO® in China, have already been included into China's National Reimbursement Drug List. Results from the BENCH
- 김갑성 기자
- 2025-07-28 10:35
Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30

- First participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1 receptor agonist ASC30. - Ultra-long-acting SQ depot formulation of small molecule ASC30 demonstrated a 36-day half-life in participants with obesity in the Phase Ib study, supporting once monthly administration. - Phase Ib study also demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ d
- 김갑성 기자
- 2025-07-28 08:15
Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 28, 2025 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the six months ended June 30, 2025 (the "Reporting Period"). Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$68 million (equivalent to approximately HK$53
- 김갑성 기자
- 2025-07-28 08:11
AESTURA, Korea's #1 Dermatologist-Recommended Dermocosmetic Brand Launches Exclusively at Sephora Australia

[ 메디채널 김갑성 기자 ] Premium dermocosmetic brand specialising in sensitive skin launches from August 26th, bringing clinically-proven innovation to Australian skincare market SYDNEY, July 28, 2025 -- AESTURA, Korea's #1 dermatologist-recommended dermocosmetic brand for sensitive skin[1], breaks new ground in the Australian skincare market with its exclusive launch at Sephora Australia stores and on Sephora.com.au, beginning August 26th, 2025. This strategic partnership with Sephora Australia answers the growing demand for advanced, science-backed solutions in the dermatologist skincare ca
- 김갑성 기자
- 2025-07-28 08:00
Elpis Biopharmaceuticals Signs Memorandum of Understanding with National Cancer Centre Singapore to Conduct Translational Cell Therapy Research in Singapore

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside SINGAPORE and LEXINGTON, Mass., July 28, 2025 -- Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of
- 김갑성 기자
- 2025-07-28 07:33
Breakthrough in Light Therapy: KouShiCare utilizes DWV™LLLT Technology to Treat Dry Eyes

HONG KONG, July 27, 2025 -- KouShiCare, a leading innovator in healthcare technology, is proud to announce a groundbreaking advancement in the treatment of dry eye disease. The company's latest device harnesses the power of DWV™ Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care. Approximately 344 million people worldwide suffer from dry eye disease. This condition causes discomfort, blurred vision, and a significant decline in quality of life. Traditional treatments, like eye drops and medications, often offer only temporary relief
- 김갑성 기자
- 2025-07-27 23:07
Xinhua Silk Road: 중국 동부 도시 룽커우, 중국 내 지속 가능한 건강•웰니스 발전의 선두주자로 부상

[ 메디채널 김갑성 기자 ] 베이징 2025년 7월 27일 -- 중국 동부에 자리한 현급 도시 룽커우가 최근 발표된 '중국 건강•웰니스 산업 연례 보고서(2024-2025)'에서 '지속 가능한 발전 역량을 갖춘 건강•웰니스 산업 100대 현'에 선정됐다. 일찌감치 건강•웰니스 산업 육성에 착수한 룽커우는 산둥성에서 현 단위 노인 돌봄 서비스 시스템 혁신 및 건강•웰니스 기반 관광 시범 도시로 지정됐다. 현지 노인 돌봄 센터에서 5년째 거주 중인 99세 천펑린(Chen Fenglin)씨는 센터의 맛있는 식사, 세심하고 배려심 많은 의료진, 우수한 서비스 품질 덕분에 항상 편안함을 느낀다고 말한다. 센터 운영을 담당하는 한유(Han Yu)씨는 "노인이 행복하게 생활하게 만들겠다는 원칙에 따라 센터는 노인과 직원들 사이에 정서적 유대감을 조성해 노인들이 요양원에서 생활하더라도 자기 집처럼 편안하게 느낄 수 있도록 노력하고 있다"고 말했다. 이 센터는 룽커우가 의료와 노인 돌봄 등 다양한 분야를 통합해 발전을 도모하고 있음을 보여주는 대표적인 사례다. 최근 몇 년 동안 룽커우시의
- 김갑성 기자
- 2025-07-27 13:49

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2025-09-01_MON

2025-08-31_SUN

2025-08-30_SAT

Global Trade Review Announces GTR Asia 2025 in Singapore - the premier platform for the trade community in the Asia Pacific region - hits over 1,500 registration for September 2-3 23:39

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 01일 09시 00분